AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01386268 — intervention group
Intervention type: BIOLOGICAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
Study NCT02784600 — intervention group
Intervention type: DEVICE
Intervention: Bioinductive implant
Study NCT01790555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namisol
Study NCT01790555 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diazepam/placebo
Study NCT01011972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-1107
Description: 6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
Study NCT02331979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Neuromodulation
Description: Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
Study NCT01557959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01557959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC
Study NCT01557959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT01557959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative study
Study NCT01557959 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative study
Study NCT01557959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative study
Study NCT01557959 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genetic linkage analysis
Description: Correlative study
Study NCT01557959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT01897649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUTRIOSE FB06
Description: 15g/day NUTRIOSE FB06
Study NCT01897649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GLUCIDEX 21
Description: 15g/day GLUCIDEX 21
Study NCT04170270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours.
Study NCT04170270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours.
Study NCT04630717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical hypnosis session
Description: the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient
Study NCT04630717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control groupe
Description: the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
Study NCT04502121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXPECT: Preoperative optimization of cardiac valve patient's expectations
Description: The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
Study NCT01983124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fotemustine + Vemurafenib
Description: Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity.
Study NCT00993499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
Study NCT00993499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (rapamycin)
Description: Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
Study NCT03908827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Mineral Aspirate Concentrate (BMAC)
Description: A single BMAC injection will be performed into the arthritic joint
Study NCT01922375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftopidil
Study NCT03510351 — intervention group
Intervention type: DRUG
Intervention: Ceftolozane-Tazobactam
Description: Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
Study NCT00334282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Oral pazopanib tablet 800 mg once daily continuously
Study NCT00334282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo (800 mg tablet) once daily
Study NCT03052140 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lamelleye Dry Eye Drops
Description: Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
Study NCT03052140 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optive Plus
Description: Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye
Study NCT02623075 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
Study NCT02623075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
Study NCT03558074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK4290
Description: ALK4290 400 mg tablet twice a day
Study NCT00453973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
Study NCT00453973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
Study NCT02978183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9% NaCl)
Description: One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
Study NCT01794273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine and phenylephrine
Study NCT02695004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-310
Study NCT00689754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube placement
Description: standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
Study NCT03328416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality
Description: The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
Study NCT01363934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1113
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.
Study NCT03351582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grief and Communication Family Intervention
Description: This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
Study NCT02695004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00125723 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PI Discretion
Description: PI Discretion
Study NCT00125723 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: PI Discretion
Description: PI Discretion
Study NCT02647333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid
Description: Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
Study NCT02647333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-6 Fatty Acid
Description: Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
Study NCT00998517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy/peanut fortified spread
Description: 75kcal/kg/day
Study NCT00998517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk fortified corn/soy blend
Description: 75 kcal/kg/day
Study NCT00998517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary Plumpy®
Description: 75 kcal/kg/day
Study NCT00583388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: L-arginine
Description: Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
Study NCT03152435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR CART
Description: EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).
Study NCT00665249 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: See MotivationalInterviewing.org
Study NCT00665249 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spirit-Only Motivational Interviewing
Description: Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
Study NCT01948973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subsensory
Description: The stimulation is here set to 90% of the sensory threshold
Study NCT00665249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Change
Description: Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
Study NCT01363934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
Study NCT01948973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OFF
Description: The stimulation is here turned OFF
Study NCT01948973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprasensory
Description: The stimulation is here set suprasensory
Study NCT00833066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: entero-coated capsules containing 25µg of gpASIT+TM
Study NCT00833066 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo entero-coated capsules
Study NCT00833066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: entero-coated capsules containing 100µg of gpASIT+TM
Study NCT00833066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: entero-coated capsules containing 400µg of gpASIT+TM
Study NCT02995018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-174)
Study NCT02995018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study NCT01064518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: RT001 (Botulinum Toxin Type A Topical Gel, Dose A) applied topically at Baseline (Day 0) to the lateral canthal lines
Study NCT01064518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Dose B)
Description: Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
Study NCT02337075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PATH program
Description: A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
Study NCT02337075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH program
Description: A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
Study NCT02337075 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity Mentor
Study NCT02337075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Mentor
Study NCT00468273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
Description: IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
Study NCT04514705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise with treadmil and weight training station
Study NCT02216539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Description: Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
Study NCT02216539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung transplantation
Study NCT02216539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung transplantation
Study NCT02216539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard post-operative pain management
Description: Post-operative pain management treatments as per usual protocols in the hospital
Study NCT02216539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-operative pain management
Description: Post-operative pain management treatments as per usual protocols in the hospital
Study NCT04121182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-line training
Description: Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia).
Study NCT04121182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice
Description: Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
Study NCT00583388 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
Study NCT04769531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Joint Mobilizations
Description: i. Anterior-posterior glide ii. Posterior-anterior glide iii. Caudal glide iv. Posterior-anterior glide with Abduction, flexion, and lateral rotation
Study NCT04769531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip joint Muscle strength training
Description: i. Hip abduction in side-lying ii. Hip extension in the prone position iii. Sideways walk iv. Hip abduction in stand up position v. Hip hitching
Study NCT04769531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knee strengthening and flexibility exercises
Description: i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:
Study NCT04769531 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: knee strengthening and flexibility exercises
Description: i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:
Study NCT04821193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin antisepsis with 5% NaHCO3 water solution
Description: In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
Study NCT04821193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin antisepsis with 2% Chlorhexidine Gluconate solution
Description: In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
Study NCT00610610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Description: Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
Study NCT00610610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same shape Placebo
Study NCT04243031 — intervention group
Intervention type: DEVICE
Intervention: QFT Access
Description: Measure of Interferon Gamma